320.56
-3.8(-1.17%)
Currency In USD
Address
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States of America
Phone
805 447 1000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
26700
First IPO Date
June 17, 1983
Name | Title | Pay | Year Born |
Mr. Robert A. Bradway | Chairman, Chief Executive Officer & President | 6.73M | 1963 |
Mr. Esteban Santos | Executive Vice President of Operations | 3.01M | 1968 |
Mr. Peter H. Griffith | Executive Vice President & Chief Financial Officer | 3.07M | 1959 |
Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | 3.24M | 1967 |
Dr. David M. Reese M.D. | Executive Vice President & Chief Technology Officer | 3.4M | 1963 |
Mr. Matthew C. Busch | Chief Accounting Officer & Vice President of Finance | 0 | 1974 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.